The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 15, 2017

Filed:

Apr. 22, 2015
Applicant:

Arena Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

Yifeng Xiong, San Diego, CA (US);

Martin C. Cherrier, Chicago, IL (US);

Jin Sun Karoline Choi, San Diego, CA (US);

Peter I. Dosa, San Diego, CA (US);

Brian M. Smith, San Diego, CA (US);

Sonja Strah-Pleynet, Newton, MA (US);

Brett Ullman, San Diego, CA (US);

Bradley Teegarden, San Diego, CA (US);

Assignee:

Arena Pharmeceuticals, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 231/14 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/04 (2006.01); C07D 231/16 (2006.01); C07D 231/54 (2006.01); C07D 403/14 (2006.01);
U.S. Cl.
CPC ...
C07D 231/16 (2013.01); C07D 231/14 (2013.01); C07D 231/54 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01);
Abstract

Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HTreceptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.


Find Patent Forward Citations

Loading…